



Association of Medical School Pediatric Department Chairs

Executive Office: 6728 Old McLean Village Drive • McLean, VA 22101-3906
Phone (703) 556-9222 • Fax (703) 556-8729 • www.ampdc.org • info@ampdc.org

AMSPDC is pleased to announce
the 8th Cohort for
Pediatric Leadership Development Program (PLDP)

Michael Bryant, M.D., M.B.A



Dr. Michael Bryant, MD, MBA, is currently the Division Chief of Hospital Medicine at Children's Hospital of Los Angeles (CHLA) where he has worked for over 20 years. He began his undergraduate education at the United States Military Academy at West Point and then earned his undergraduate degree in Physiology at the University of California at Davis in 1983. He obtained his Medical Degree at the University of Cincinnati College of Medicine in 1987 and his Masters in Business Administration from the Anderson School of Business at UCLA in 2003. Dr. Bryant has held numerous clinical positions at CHLA and was most recently the Deputy Head of the Division of General Pediatrics before becoming Head of the newly formed Division of Hospital Medicine in November of 2009. He has served on the Board of the physician practice at CHLA for many years, Children's Hospital Medical Group (CHLAMG), chairing its Operations and Business Development Committees, as well as serving as Vice President of the Board and a member of the Contracting Kitchen Cabinet. Dr. Bryant has also served as a Trustee on the Board of Alta Med Health Services Corporation and chaired its Quality Review Committee as well as the Boards of several community organizations including Park Century School and the Hollywood School House.

Jennifer Friedman, PhD, M.D.



Dr. Jennifer Friedman is a graduate of Brown University (Magna cum Laude, 1992) where she also was awarded the MD degree in 1996. During medical school, she received a Fulbright Scholarship to conduct postdoctoral research at the Centers for Disease Control and Prevention's (CDC) field station in Kisumu, Kenya. She then completed her residency in Pediatrics at the Children's Hospital of Philadelphia in 2000 and went on to complete a fellowship in General Pediatrics at the Boston Children's Hospital and earned an MPH from Harvard in 2002. During her fellowship, Dr. Friedman wrote a successful NIH K award, which allowed her to join the Department of Pediatrics at Hasbro in 2002. Together with a colleague in Pathology, she co-founded the Center for International Health Research at Rhode Island Hospital in 2005, first as the Director of Clinical Studies and now as Center Director. She completed her PhD (2006) in Epidemiology and Biostatistics based on work from Kenya and her fellowship at Boston Children's. Throughout this time, she has mostly dedicated her effort to maternal-child global health research and also devotes 20% effort as a practicing pediatrician in the Division of Ambulatory Pediatrics at the Hasbro Children's Hospital. Dr. Friedman became Director of this Division in 2016.

Her career has largely focused on collaborative NIH and Foundation grants addressing mechanisms of parasitic disease morbidity among women and children and identifying best approaches to mitigate this. Dr. Friedman's collaborative work has helped established schistosomiasis as a chronic inflammatory disease culminating in pediatric undernutrition, anemia of inflammation, and adverse pregnancy outcomes. Together with collaborators, she has published close to 70 manuscripts in this area. This includes a pivotal manuscript in *Lancet Infectious Diseases*, which reported results of an NIH/NIAID funded clinical trial of Praziquantel treatment for pregnant women with schistosomiasis, for which she served as Principal Investigator. This contribution demonstrated that praziquantel is safe and efficacious for the treatment of schistosomiasis during human pregnancy. This has expanded use of this therapeutic for millions of women who had gone untreated globally.

During her career, Dr. Friedman has also had the privilege to provide scientific mentorship for over 25 individuals at various stages of career development, including primary mentorship of 6 clinical junior faculty members and four post-doctoral students. In 2015, she received an NIH K24 "Mentoring" award to provide dedicated time to mentor physician scientists conducting patient-oriented research. She taken on leadership roles at her institution and nationally, for example as Associate Editor for *PLoS NTD* and chair of the Schistosomiasis Scientific Committee for our international organization, American Society of Tropical Medicine

and Hygiene. Dr. Friedman is also currently working with World Health Organization and the US FDA to update the pregnancy labeling for Praziquantel, including a recent publication in the Bulletin of the WHO addressing this.

Amy Brooks-Kayal, MD



Dr. Amy Brooks-Kayal is a Professor of Pediatrics, Neurology and Pharmaceutical Sciences, Section Head and Ponzio Family Chair of Pediatric Neurology, and Co-director of the Translational Epilepsy Research Program at the University of Colorado School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences, and Children's Hospital Colorado. She trained in Pediatrics and Neurology at Johns Hopkins University, University of Pennsylvania and Children's Hospital of Philadelphia. She joined the University of Colorado in 2008 after 13 years on the faculty at University of Pennsylvania and Children's Hospital of Philadelphia. Her area of clinical focus is pediatric epilepsy and her research focuses on regulation of neurotransmitter systems during epilepsy and epileptogenesis, with particular emphasis on GABAA receptor expression regulation by the JAK/STAT pathway, and targeting these molecular changes to develop disease modifying therapy.

Dr. Brooks-Kayal has benefited from leadership opportunities at an institutional and national level. In the past 10 years under her leadership, the section of Pediatric Neurology and Neuroscience Institute at Children's Hospital Colorado and University of Colorado has experienced tremendous growth in its size, capabilities and national reputation. She is also a Past President and previous member of the Executive committee and Board of Directors of the American Epilepsy Society, a member of the NIH/NINDS Advisory Council and Commission on North American Affairs of the International League Against Epilepsy, a Director of the American Board of Psychiatry and Neurology, and an active member of the American Neurological Association, Child Neurology Society, Society for Neuroscience and American Academy of Neurology.

Steven G. Kernie, M.D.



Dr. Steven Kernie is a Professor of Pediatrics (in Neurology) at Columbia University in New York and Chief of Critical Care Medicine at New York Presbyterian Morgan Stanley Children's Hospital at the Columbia University Irving Medical Center. His research interests focus on acquired brain injuries in children and he leads a laboratory that investigates how the brain repairs itself following injury.

After studying Human Biology at Stanford University, Dr. Kernie obtained his M.D. degree from the University of Washington in 1992. He was a pediatrics resident, chief resident, and pediatric critical care fellow at UT Southwestern Medical Center/Children's Medical Center Dallas from 1992 to 1999. During his fellowship, he joined the laboratory of Luis Parada, Ph.D., where he studied how neurotrophins affect feeding behavior in mice. Dr. Kernie then developed an independent research program investigating how the brain repairs itself following acquired brain injuries due to trauma and hypoxia. He was on the faculty at UT Southwestern from 1999 to 2011 where he established a laboratory on brain injury and continued to care for patients in the PICU at Children's Medical Center Dallas. During that time, he was the director of the pediatric critical care fellowship program at UT Southwestern/Children's Medical Center Dallas, the medical director for research administration at Children's Medical Center Dallas, and the co-director of the Perot Family Center for Brain and Nerve Injuries at Children's Medical Center Dallas. He was recruited to Columbia in 2011 to be chief of the division of pediatric critical care medicine and director of critical care services at New York Presbyterian Morgan Stanley Children's Hospital.

Dr. Kernie's laboratory is focused on elucidating mechanisms of brain self-repair following injury. The Kernie lab has developed a number of novel mouse transgenic animals that allow for specific ablation or activation of hippocampal neural stem cells, which are known to provide neurons to critical areas of the brain throughout life. His lab was the first to describe the phenomenon of injury-induced neurogenesis and subsequently experimentally demonstrated that this response is required for recovery

from traumatic brain injury. These studies have been highlighted in Scientific American, US News and World Reports, and Science News for their impact on how we view and potentially treat devastating brain injuries in children and adults. Since joining Columbia University, he remains focused on these lab-based studies that investigate mechanisms underlying self-repair following injury and he has maintained continual funding from the NIH for his work since 2001.

Ian M. Paul, MD, MSc



Dr. Ian Paul Professor of Pediatrics and Public Health Sciences at the Pennsylvania State University College of Medicine, Chief of the Division of Academic General Pediatrics and Vice Chair of Clinical Affairs in the Department of Pediatrics at Penn State Children's Hospital in Hershey, PA. His education includes receipt of a B.A. from Franklin and Marshall College (cum laude) with a major in Chemistry (with honors), graduate degrees (M.D. and M.Sc.) from The Penn State College of Medicine, and completion of a pediatric residency at Duke University.

For the past 16 years, Dr. Paul has been a general pediatrician and clinical and health services researcher with principal interests in both primary preventive interventions for newborns, infants, and families and clinical therapeutics for children. His research focuses on these two areas with the largest current NIH/NIDDK-funded projects focusing on the prevention of childhood obesity through home-based interventions delivered to parents of infants. His team's work in this field includes the first ever study to demonstrate that behavioral interventions delivered in the months after birth can lead to slower weight gain through age 1 year. He has also been funded by HRSA/MCHB on projects related to newborn weight loss and breastfeeding, research that generated the first ever nomograms depicting newborn weight loss for exclusively breastfed and exclusively formula fed term neonates during the birth hospitalization. He is a co-investigator on numerous NIH-funded projects related to co-parenting, infant sleep, prevention of Shaken Baby Syndrome, prevention of adverse pregnancy outcomes and the treatment of asthma, the latter through participation as a co-investigator on the NHLBI-funded network, AsthmaNet. In total, Dr. Paul has published over 100 peer-reviewed scientific publications including those published in the *New England Journal of Medicine*, *Proceedings of the National Academy of Sciences*, *JAMA Pediatrics*, *Pediatrics*, *Obesity*, *Annals of Emergency Medicine*, and *Journal of Allergy and Clinical Immunology*.

Dr. Paul has held leadership positions with the American Academy of Pediatrics including service on the Committee on Drugs (2010-2016). He is also a steering committee member for the NIH's Pediatric Trials Network (PTN), co-investigator for the Coordinating Center for NIH's Environmental Influences on Child Health Outcomes (ECHO) network, and a participant in the CDC's PROTECT initiative, which seeks to prevent unintended ingestions and overdoses of medications by children. He is currently a standing member of NIH's Psychosocial Risk and Disease Prevention (PRDP) study section.